In a single day, the talk on the Street has zeroed in on one stock, oncology-focused cell therapy company Adaptimmune Therapeutics (ADAP). Following its presentation of promising data at the 38th ...
Albertan man Bruce Johnson said the impending change from AISH to ADAP, which will provide less money to those who receive ...
We expect investors to focus on pipeline updates when Adaptimmune Therapeutics ADAP reports second-quarter 2023 results next month. Adaptimmune has an impeccable record of earnings surprises in recent ...
Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) shares are trading higher by 15.8% to $1.17 during Friday’s session after the company and Galapagos entered a clinical collaboration to license ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results